PMID- 33921475
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 8
DP  - 2021 Apr 12
TI  - Thapsigargin-Stimulated LAD2 Human Mast Cell Line Is a Potent Cellular Adjuvant 
      for the Maturation of Monocyte-Derived Dendritic Cells for Adoptive Cellular 
      Immunotherapy.
LID - 10.3390/ijms22083978 [doi]
LID - 3978
AB  - The preparation of dendritic cells (DCs) for adoptive cellular immunotherapy 
      (ACI) requires the maturation of ex vivo-produced immature(i) DCs. This 
      maturation ensures that the antigen presentation triggers an immune response 
      towards the antigen-expressing cells. Although there is a large number of 
      maturation agents capable of inducing strong DC maturation, there is still only a 
      very limited number of these agents approved for use in the production of DCs for 
      ACI. In seeking novel DC maturation agents, we used differentially activated 
      human mast cell (MC) line LAD2 as a cellular adjuvant to elicit or modulate the 
      maturation of ex vivo-produced monocyte-derived iDCs. We found that co-culture of 
      iDCs with differentially activated LAD2 MCs in serum-containing media 
      significantly modulated polyinosinic:polycytidylic acid (poly I:C)-elicited DC 
      maturation as determined through the surface expression of the maturation markers 
      CD80, CD83, CD86, and human leukocyte antigen(HLA)-DR. Once iDCs were generated 
      in serum-free conditions, they became refractory to the maturation with poly I:C, 
      and the LAD2 MC modulatory potential was minimized. However, the 
      maturation-refractory phenotype of the serum-free generated iDCs was largely 
      overcome by co-culture with thapsigargin-stimulated LAD2 MCs. Our data suggest 
      that differentially stimulated mast cells could be novel and highly potent 
      cellular adjuvants for the maturation of DCs for ACI.
FAU - Taborska, Pavla
AU  - Taborska P
AUID- ORCID: 0000-0001-5935-5656
AD  - Department of Immunology, Second Faculty of Medicine, Charles University and 
      University Hospital Motol, 15006 Prague, Czech Republic.
FAU - Stakheev, Dmitry
AU  - Stakheev D
AD  - Department of Immunology, Second Faculty of Medicine, Charles University and 
      University Hospital Motol, 15006 Prague, Czech Republic.
FAU - Bartunkova, Jirina
AU  - Bartunkova J
AD  - Department of Immunology, Second Faculty of Medicine, Charles University and 
      University Hospital Motol, 15006 Prague, Czech Republic.
FAU - Smrz, Daniel
AU  - Smrz D
AUID- ORCID: 0000-0003-0143-8744
AD  - Department of Immunology, Second Faculty of Medicine, Charles University and 
      University Hospital Motol, 15006 Prague, Czech Republic.
LA  - eng
GR  - PRIMUS/MED/12/Univerzita Karlova v Praze/
GR  - AZV 16-28135A/Ministerstvo Zdravotnictvi Ceske Republiky/
PT  - Journal Article
DEP - 20210412
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Adjuvants, Immunologic)
RN  - 67526-95-8 (Thapsigargin)
SB  - IM
MH  - Adjuvants, Immunologic/pharmacology
MH  - Antigen Presentation/drug effects/immunology
MH  - Cell Culture Techniques/*methods
MH  - Cell Differentiation/drug effects
MH  - Coculture Techniques
MH  - Dendritic Cells/cytology/*drug effects/immunology
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Mast Cells/cytology/*drug effects/immunology
MH  - Monocytes/cytology/drug effects/immunology
MH  - Thapsigargin/pharmacology
PMC - PMC8069665
OTO - NOTNLM
OT  - LAD2 human mast cells
OT  - adoptive cellular immunotherapy
OT  - dendritic cells
OT  - maturation
COIS- J.B. is a part-time employee and a minority shareholder of Sotio, a.s., a biotech 
      company developing cell-based immunotherapy. P.T., D.S. (Dmitry Stakheev), and 
      D.S. (Daniel Smrz) declare no conflicts of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/13 06:00
PMCR- 2021/04/12
CRDT- 2021/04/30 01:19
PHST- 2021/03/02 00:00 [received]
PHST- 2021/03/23 00:00 [revised]
PHST- 2021/04/07 00:00 [accepted]
PHST- 2021/04/30 01:19 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2021/04/12 00:00 [pmc-release]
AID - ijms22083978 [pii]
AID - ijms-22-03978 [pii]
AID - 10.3390/ijms22083978 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Apr 12;22(8):3978. doi: 10.3390/ijms22083978.